These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533 [TBL] [Abstract][Full Text] [Related]
23. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748 [TBL] [Abstract][Full Text] [Related]
24. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
25. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Chen Y; Hu H; Yuan X; Fan X; Zhang C Front Immunol; 2022; 13():896752. PubMed ID: 35757756 [TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. Guardascione M; Toffoli G Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115 [TBL] [Abstract][Full Text] [Related]
27. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460 [TBL] [Abstract][Full Text] [Related]
28. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Saffo S; Taddei TH Dig Dis Sci; 2019 Apr; 64(4):1016-1029. PubMed ID: 30887150 [TBL] [Abstract][Full Text] [Related]
29. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements. Sun Y; Zhang W; Bi X; Yang Z; Tang Y; Jiang L; Bi F; Chen M; Cheng S; Chi Y; Han Y; Huang J; Huang Z; Ji Y; Jia L; Jiang Z; Jin J; Jin Z; Li X; Li Z; Liang J; Liu L; Liu Y; Lu Y; Lu S; Meng Q; Niu Z; Pan H; Qin S; Qu W; Shao G; Shen F; Song T; Song Y; Tao K; Tian A; Wang J; Wang W; Wang Z; Wu L; Xia F; Xing B; Xu J; Xue H; Yan D; Yang L; Ying J; Yun J; Zeng Z; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhou J; Zhu X; Zou Y; Dong J; Fan J; Lau WY; Sun Y; Yu J; Zhao H; Zhou A; Cai J Liver Cancer; 2022 Jun; 11(3):192-208. PubMed ID: 35949289 [TBL] [Abstract][Full Text] [Related]
30. Systemic treatment for unresectable hepatocellular carcinoma. Leowattana W; Leowattana T; Leowattana P World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588 [TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. Mandlik DS; Mandlik SK; Choudhary HB World J Gastroenterol; 2023 Feb; 29(6):1054-1075. PubMed ID: 36844141 [TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Harding JJ Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837 [TBL] [Abstract][Full Text] [Related]
33. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677 [TBL] [Abstract][Full Text] [Related]
34. Systemic therapy of liver cancer. Demir T; Lee SS; Kaseb AO Adv Cancer Res; 2021; 149():257-294. PubMed ID: 33579425 [TBL] [Abstract][Full Text] [Related]
35. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Huang JT; Zhang S; Yang YH; Zhang ZC; Jiang N; Li WC; Shen J; Zhong BY; Zhu XL Clin Med Insights Oncol; 2022; 16():11795549221134832. PubMed ID: 36387611 [TBL] [Abstract][Full Text] [Related]
36. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856 [TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Ouyang T; Kan X; Zheng C Front Oncol; 2022; 12():898964. PubMed ID: 35785169 [TBL] [Abstract][Full Text] [Related]
38. Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Nakano S; Eso Y; Okada H; Takai A; Takahashi K; Seno H Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218257 [TBL] [Abstract][Full Text] [Related]
39. Recent advances in systemic therapy for hepatocellular carcinoma. Zhang H; Zhang W; Jiang L; Chen Y Biomark Res; 2022 Jan; 10(1):3. PubMed ID: 35000616 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]